Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

S&P Biotech SPDR (XBI)

S&P Biotech SPDR (XBI)
84.04 x 100 84.10 x 100
Post-market by (Cboe BZX)
84.40 -1.13 (-1.32%) 03/28/25 [NYSE Arca]
84.04 x 100 84.10 x 100
Post-market 84.10 -0.30 (-0.36%) 19:59 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
83.97
Day High
85.51
Open 85.40
Previous Close 85.53 85.53
Volume 7,003,100 7,003,100
Avg Vol 8,090,750 8,090,750
Stochastic %K 18.42% 18.42%
Weighted Alpha -11.06 -11.06
5-Day Change -2.72 (-3.12%) -2.72 (-3.12%)
52-Week Range 81.14 - 105.47 81.14 - 105.47
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Price/Earnings ttm 17.88
  • Annual Dividend & Yield 0.14 (0.16%)
  • Most Recent Dividend 0.005 on 03/24/25
  • Management Fee 0.35%
  • INDUSTRY GROUPING:

    ETFs - Biotech

Options Overview Details

View History
  • Implied Volatility 29.03% ( +5.16%)
  • Historical Volatility 23.00%
  • IV Percentile 70%
  • IV Rank 39.77%
  • IV High 38.19% on 08/05/24
  • IV Low 22.98% on 11/12/24
  • Put/Call Vol Ratio 1.27
  • Today's Volume 64,644
  • Volume Avg (30-Day) 38,172
  • Put/Call OI Ratio 1.42
  • Today's Open Interest 503,874
  • Open Int (30-Day) 563,193

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.97 +0.51%
on 03/28/25
Period Open: 88.71
89.37 -5.56%
on 03/03/25
-4.31 (-4.86%)
since 02/28/25
3-Month
83.97 +0.51%
on 03/28/25
Period Open: 91.35
94.90 -11.06%
on 02/05/25
-6.95 (-7.61%)
since 12/27/24
52-Week
81.14 +4.02%
on 04/25/24
Period Open: 94.89
105.47 -19.98%
on 11/11/24
-10.49 (-11.05%)
since 03/28/24

Most Recent Stories

More News
Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks

The company expects the drug, the first approved therapy to address hyperphagia in PWS patients, to be available in the U.S. starting April 2025.

VTI : 273.43 (-1.99%)
SLNO : 71.99 (+6.83%)
XBI : 84.40 (-1.32%)
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up

Jefferies acknowledged acute liver failure could signal a new safety risk but maintained that the high unmet need for DMD treatments supports the bull case.

SRPT : 70.41 (-1.95%)
IJH : 58.21 (-1.80%)
VTI : 273.43 (-1.99%)
XBI : 84.40 (-1.32%)
Capricor Therapeutics Stock Surges After Q4 Results Beat Estimates: Retail Gets More Bullish

The company said its available cash, cash equivalents, and marketable securities will be sufficient to cover the expenses and capital requirements into 2027.

VTI : 273.43 (-1.99%)
XBI : 84.40 (-1.32%)
CAPR : 11.50 (-2.67%)
How Is Biogen's Stock Performance Compared to Other Biotech Stocks?

Despite Biogen's underperformance compared to other biotech stocks over the past year, analysts remain moderately optimistic about its future prospects.

GILD : 111.79 (+0.57%)
XBI : 84.40 (-1.32%)
BIIB : 138.37 (-1.40%)
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.

ALT : 5.32 (-4.49%)
VTI : 273.43 (-1.99%)
IWM : 200.45 (-2.03%)
XBI : 84.40 (-1.32%)
Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss

Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.

SGMO : 0.8200 (-4.35%)
VTI : 273.43 (-1.99%)
XBI : 84.40 (-1.32%)
SCHA : 23.48 (-2.13%)
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

VTI : 273.43 (-1.99%)
XBI : 84.40 (-1.32%)
IWM : 200.45 (-2.03%)
SWTX : 47.41 (-0.17%)
Capricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD Therapy

The health agency has accepted Capricor's Biologics License Application for full approval of deramiocel as a treatment for Duchenne muscular dystrophy cardiomyopathy.

VTI : 273.43 (-1.99%)
XBI : 84.40 (-1.32%)
IWM : 200.45 (-2.03%)
CAPR : 11.50 (-2.67%)
Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.

EBS : 4.66 (-5.28%)
AVUV : 87.12 (-2.04%)
VTI : 273.43 (-1.99%)
XBI : 84.40 (-1.32%)
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week

Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year.

TGTX : 39.86 (-0.85%)
IJR : 104.01 (-2.16%)
VTI : 273.43 (-1.99%)
XBI : 84.40 (-1.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Fund Summary

The SPDR SP Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the SP Biotechnology Select Industry Index.

See More

Key Turning Points

3rd Resistance Point 86.82
2nd Resistance Point 86.17
1st Resistance Point 85.28
Last Price 84.40
1st Support Level 83.74
2nd Support Level 83.09
3rd Support Level 82.20

See More

52-Week High 105.47
Fibonacci 61.8% 96.18
Fibonacci 50% 93.31
Fibonacci 38.2% 90.43
Last Price 84.40
52-Week Low 81.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies